SCHEMBL4760486

SCHEMBL4760486

COC(=O)c1ccc(CCBr)c(C(=O)OC)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.50
ALDH1A1 P00352 9/20 0.50
MAPT P10636 5/20 0.50
HSD17B10 Q99714 5/20 0.50
HPGD P15428 4/20 0.50
GLA P06280 2/20 0.50
GAA P10253 2/20 0.50
CASP1 P29466 1/20 0.50
CASP7 P55210 1/20 0.50
ATM Q13315 1/20 0.50
CA12 O43570 2/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA7 P43166 2/20 0.46
CA9 Q16790 2/20 0.46
CA14 Q9ULX7 2/20 0.46
XDH P47989 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.44
KMT2A Q03164 2/20 0.43
LMNA P02545 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2065651 0.87 KDM4E (0.53) KDM4EALDH1A1MAPTHSD17B10HPGD
SCHEMBL27594634 0.84 NOTUM (0.53) KDM4EALDH1A1MAPTHSD17B10HPGD
SCHEMBL28761815 0.84 MAPT (0.48) KDM4EALDH1A1MAPTHSD17B10HPGD
SCHEMBL6617704 0.84 MAPT (0.46) KDM4EALDH1A1MAPTHSD17B10HPGD
SCHEMBL16056048 0.84 NR4A2 (0.47) ALDH1A1MAPTHSD17B10HPGDGAA
SCHEMBL28752184 0.83 ALDH1A1 (0.48) KDM4EALDH1A1MAPTHSD17B10HPGD
SCHEMBL5832949 0.83 MAPT (0.54) KDM4EMAPTATMCA12CA1
SCHEMBL27792226 0.83 KDM4E (0.53) KDM4EALDH1A1MAPTHSD17B10HPGD
SCHEMBL4278401 0.83 ABL1 (0.51) KDM4EALDH1A1HPGDKMT2ALMNA
SCHEMBL5251504 0.81 KDM4E (0.54) KDM4EALDH1A1MAPTHSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7413727-B2 Contrast agents GE HEALTHCARE AS (NO) 2008-08-19 US disclosed
EP-1442751-B1 Diagnostic imaging technique GE HEALTHCARE AS (NO) 2007-06-20 EP disclosed
CN-1886376-A Pyridine compounds as dipeptidyl dipeptidase-IV inhibitors TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2006-12-27 CN disclosed
EP-1442751-A1 Method of imaging Amersham Health AS (NO) 2004-08-04 EP disclosed
EP-0977600-B1 CONTRAST AGENTS TARGETTING RECEPTORS ASSOCIATED WITH ANGIOGENESIS AMERSHAM HEALTH AS (NO) 2004-06-30 EP disclosed
US-20040009122-A1 Contrast agents AMERSHAM HEALTH AS (NO) 2004-01-15 US disclosed
EP-0977600-A2 CONTRAST AGENTS NYCOMED IMAGING A/S (NO) 2000-02-09 EP disclosed
WO-1998047541-A1 CONTRAST AGENTS NYCOMED IMAGING AS (NO) 1998-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009122-A1 Contrast agents FLT1, FLT4, KDR KDM4E 4102/4885ALDH1A1 4212/4885MAPT 2106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.